20.63
0.16 (0.78%)
| Penutupan Terdahulu | 20.47 |
| Buka | 20.30 |
| Jumlah Dagangan | 335,491 |
| Purata Dagangan (3B) | 213,812 |
| Modal Pasaran | 705,805,888 |
| Harga / Buku (P/B) | 3.93 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 13 Aug 2025 - 18 Aug 2025 |
| EPS Cair (TTM) | -3.76 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.07% |
| Nisbah Semasa (MRQ) | 14.34 |
| Aliran Tunai Operasi (OCF TTM) | -119.59 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -54.54 M |
| Pulangan Atas Aset (ROA TTM) | -23.10% |
| Pulangan Atas Ekuiti (ROE TTM) | -49.00% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menurun | Menurun |
| Biotechnology (Global) | Menurun | Menurun | |
| Stok | ArriVent BioPharma, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 1.0 |
| Purata Bergerak Teknikal | 1.5 |
| Osilator Teknikal | 2.0 |
| Purata | 2.38 |
|
ArriVent BioPharma Inc is a clinical stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize team’s deep drug development experience to maximize the potential of lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 9.74% |
| % Dimiliki oleh Institusi | 85.20% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Hidden Lake Asset Management Lp | 31 Mar 2025 | 254,371 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 40.00 (HC Wainwright & Co., 93.89%) | Beli |
| 40.00 (Jones Trading, 93.89%) | Beli | |
| Median | 40.00 (93.89%) | |
| Rendah | 37.00 (B. Riley Securities, 79.35%) | Beli |
| Purata | 39.00 (89.05%) | |
| Jumlah | 3 Beli | |
| Harga Purata @ Panggilan | 19.72 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Jones Trading | 20 May 2025 | 40.00 (93.89%) | Beli | 20.86 |
| HC Wainwright & Co. | 14 May 2025 | 40.00 (93.89%) | Beli | 18.75 |
| B. Riley Securities | 20 Mar 2025 | 37.00 (79.35%) | Beli | 19.54 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 12 May 2025 | Pengumuman | ArriVent BioPharma Reports First Quarter 2025 Financial Results |
| 28 Apr 2025 | Pengumuman | ArriVent BioPharma Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |